Adjuvant Therapy of Operable Primary Osteosarcoma-Cancer and Leukemia Group B Experience

  • E. P. Cortes
  • J. F. Holland
  • O. Glidewell
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 68)

Abstract

The major therapeutic approach to primary osteogenic sarcoma has, for many years, been radical surgery. Despite differences in pretherapeutic work-up, surgical techniques, and demography, the overall survival rates in the review of Friedman and Carter was 19.7% (253 of 1286 patients) [8]. The range was fairly small, 16%–23% in the series published. Radiologic evidence of pulmonary metastases occurs at a median of 8.5 months after potentially curative amputation [10]. The patient usually dies within 6 months from the onset of detectable pulmonary metastases [13].

Keywords

Toxicity Leukemia Creatinine Pneumonia Oncol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Reference

  1. 1.
    Cortes, E. P., Holland, J. F., Wang, J. J. et al.: Doxorubicin in disseminated osteosarcoma. JAMA 221, 1132–1138 (1972).CrossRefGoogle Scholar
  2. 2.
    Cortes, E. P., Holland, J. F., Wang, J. J. et al.: Chemotherapy of advanced osteosarcoma. Colston paper No. 24. In: Bone-certain aspects of neoplasia price, CHG, Rose, F. G. M. (eds.), pp. 265–280. London: Butterworth 1972.Google Scholar
  3. 3.
    Cortes, E. P., Holland, J. F., Wang, J. J. et al.: Amputation and adriamycin in primary osteosarcoma. N. Engl. J. Med. 291, 998–1000 (1974).PubMedCrossRefGoogle Scholar
  4. 4.
    Cortes, E. P., Holland, J. F., Wang, J. J. et al.: Adriamycin (NSC-123127) in 87 patients with osteosarcoma. Cancer Chemother. Rep. (Part 3) 6, 305–313 (1975).Google Scholar
  5. 5.
    Cortes, E. P., Lutman, G., Wanka, J. et al.: Adriamycin (NSC-123127) cardiotoxicity: a clinicopathologic correlation. Cancer Chemother. Rep. (Part 3), 6, 215–225 (1975).Google Scholar
  6. 6.
    Cortes, E. P., Holland, J. F., Glidewell, O.: Amputation and adriamycin in primary osteosarcoma: a 5-year report. Cancer Treat. Rep. 62, 271–277 (1978).PubMedGoogle Scholar
  7. 7.
    Enneking, R. W. F., Kagan, A.: “Skip” metastases in osteosarcoma. Cancer 36, 2192–2205 (1975).PubMedCrossRefGoogle Scholar
  8. 8.
    Friedman, M. A., Carter, S. K.: The therapy of osteogenic sarcoma: current status and thoughts for the future. J. Surg. Oncol. 4, 482–510 (1972).PubMedCrossRefGoogle Scholar
  9. 9.
    Jaffe, N.: Recent advances in the chemotherapy of metastatic osteogenic sarcoma. Cancer 30, 1627–1631 (1972).PubMedCrossRefGoogle Scholar
  10. 10.
    Marcove, R. C., Mike, V., Hajek, J. V. et al.: Osteogenic sarcoma in childhood. NY State J. Med. 71, 855–859 (1971).Google Scholar
  11. 11.
    McKenna, R. J., Schwinn, C. P., Soong, K. Y. et al.: Sarcoma of the osteogenic series (osteosarcoma, fibrosarcoma, chondrosarcoma, parosteal osteogenic sarcoma, and sarcomata arising in abnormal bone): an analysis of 552 cases. J. Bone Joint Surg. 48, 1–26 (1966).Google Scholar
  12. 12.
    Scranton, P. E., DeCicco, F. A., Totten, R. S. et al.: Prognostic factors in osteosarcoma. Cancer 36, 2179–2191 (1975).PubMedCrossRefGoogle Scholar
  13. 13.
    Sweetnam, R.: Amputation in osteosarcoma. J. Bone Joint Surg. 55 B, 189–192 (1973).Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1979

Authors and Affiliations

  • E. P. Cortes
  • J. F. Holland
  • O. Glidewell

There are no affiliations available

Personalised recommendations